Potential and Challenges for Start-ups in Japan’s Biotech Industry

Although Japan has both a globally rare national mandated healthcare program and one of the most extensive life science research capabilities in the world, there is a future risk of their divergence due to Japan’s aging citizenry and the patent cliff of blockbuster drugs in domestic pharmaceutical industry. In order to bridge the gap between the research findings and the healthcare welfare with innovative new drugs under a prolonged drug...